Slingshot members are tracking this event:

FDA Approves Expanded Labeling for Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sofosbuvir, Velpatasvir, Epclusa, Chronic Hepatitis C, Hiv